CrossrefInfokarte
Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling
Drug Resistance Updates · 2026-09 · 88 · 101440
DOI: 10.1016/j.drup.2026.101440 ↗Abstract
Kein Abstract verfügbar.
EUVIMED